Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
← catalyst calendarNCT07185256 · readout ≤ 1,472 d
Sponsored by Opus Genetics, Inc (industry) · IRD — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-25 | actual | When the study began enrolling |
| Primary completion | Aug 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- ARB
- BVMD
- Autosomal-Dominant Bestrophinopathy
- Best Vitelliform Macular Dystrophy
Intervention
- Genetic: OPGx-BEST1
Primary outcomes
what the primary-completion date above is the date OFNumber of dose-limiting toxicity (DLT) events at the dose tested
measured 5 years
Number and severity of procedure-related adverse events
measured 5 years
Number and severity of adverse events related to OPGx-BEST1
measured 5 years
Permalink · IRD's whole pipeline · Catalyst calendar · Every registered study · What changed